Solid Biosciences LLC (SLDB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Solid Biosciences LLC (SLDB) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-47.23 Million) by net assets ($374.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Solid Biosciences LLC to measure how much of total assets are equity-financed.
Solid Biosciences LLC - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Solid Biosciences LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SLDB total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Solid Biosciences LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solid Biosciences LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Swissquote Group Holding SA
SW:SQN
|
0.300x |
|
Miracll Chemicals Co Ltd
SHE:300848
|
0.054x |
|
Bear Electric Appliance Co Ltd
SHE:002959
|
-0.001x |
|
Jiangsu Lianyungang Port Co Ltd
SHG:601008
|
-0.038x |
|
New York Mortgage Trust, Inc.
NASDAQ:ADAM
|
-0.011x |
|
Thunder Tiger Corp
TW:8033
|
-0.014x |
|
VBG Group AB (publ)
ST:VBG-B
|
0.022x |
|
Capital City Bank Group
NASDAQ:CCBG
|
0.028x |
Annual Cash Flow Conversion Efficiency for Solid Biosciences LLC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Solid Biosciences LLC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Solid Biosciences LLC market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $180.01 Million | $-156.29 Million | -0.868x | -19.15% |
| 2024-12-31 | $137.25 Million | $-100.01 Million | -0.729x | +2.14% |
| 2023-12-31 | $126.48 Million | $-94.18 Million | -0.745x | -60.86% |
| 2022-12-31 | $211.67 Million | $-97.98 Million | -0.463x | -23.94% |
| 2021-12-31 | $208.21 Million | $-77.76 Million | -0.373x | +12.84% |
| 2020-12-31 | $132.09 Million | $-56.60 Million | -0.429x | +63.00% |
| 2019-12-31 | $80.05 Million | $-92.71 Million | -1.158x | -106.55% |
| 2018-12-31 | $125.18 Million | $-70.20 Million | -0.561x | -176.88% |
| 2017-12-31 | $-59.26 Million | $-43.22 Million | 0.729x | +37.35% |
| 2016-12-31 | $-37.89 Million | $-20.12 Million | 0.531x | +151.70% |
| 2015-12-31 | $-19.93 Million | $-4.20 Million | 0.211x | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more